NASDAQ:SION Sionna Therapeutics (SION) Stock Price, News & Analysis $3.07 -0.05 (-1.60%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$3.12 +0.05 (+1.56%) As of 11/17/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sionna Therapeutics Stock (NASDAQ:SION) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sionna Therapeutics alerts:Sign Up Key Stats Today's Range$2.99▼$3.1750-Day Range$3.07▼$8.2652-Week Range$2.99▼$54.97Volume550,734 shsAverage Volume855,090 shsMarket Capitalization$138.89 millionP/E RatioN/ADividend YieldN/APrice Target$42.33Consensus RatingHold Company Overview Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, a genetic disease caused by defects in the CFTR protein. The company’s research aims to address the underlying protein dysfunction rather than only manage the symptoms of the disease. Its pipeline includes small-molecule candidates designed to stabilize or correct CFTR, with the goal of restoring the protein’s function. Sionna is investigating these candidates as potential components of combination therapies for people with cystic fibrosis. Founded in 2019 and based in Cambridge, Massachusetts, Sionna develops therapies for a disease affecting patients worldwide. Its programs remain in development, and the company’s focus is on advancing new treatment options for the cystic fibrosis community.AI Generated. May Contain Errors. Read More Sionna Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreSION MarketRank™: 1.854366347175 of 5 starsSionna Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 690th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingSionna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 11 hold ratings, and 1 sell rating.Upside PotentialSionna Therapeutics has a consensus price target of $42.33, representing about 1,278.9% upside from its current price of $3.07.Amount of Analyst CoverageSionna Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Sionna Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sionna Therapeutics are expected to grow in the coming year, from ($2.54) to ($2.10) per share.Price to Book Value per Share RatioSionna Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.82% of the float of Sionna Therapeutics has been sold short.Short Interest Ratio / Days to CoverSionna Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Sionna Therapeutics has recently increased by 14.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSionna Therapeutics does not currently pay a dividend.Dividend GrowthSionna Therapeutics does not have a long track record of dividend growth. News and Social Media1.1 / 5News SentimentN/A News SentimentSionna Therapeutics has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sionna Therapeutics this week, compared to 4 articles on an average week. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sionna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,830,974.00 in company stock.Percentage Held by Insiders5.10% of the stock of Sionna Therapeutics is held by insiders.Percentage Held by InstitutionsSionna Therapeutics has minimal institutional ownership at this time.Read more about Sionna Therapeutics' insider trading history. Receive SION Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sionna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SION Stock News HeadlinesSionna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12, 2026 | marketscreener.comMSionna Therapeutics Q3 2026: Miss, Layoffs, and a 2029 Cash RunwayNovember 10, 2026 | 247wallst.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected. | Porter & Company (Ad)Sionna Therapeutics Reports Third Quarter 2026 Financial ResultsNovember 10, 2026 | globenewswire.comSionna Therapeutics: The Market May Be Wrong About The Science, But Right About The StockNovember 6, 2026 | seekingalpha.comSionna Therapeutics to Participate in Upcoming November 2026 Investor ConferencesNovember 2, 2026 | globenewswire.comSionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis ConferenceOctober 8, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONOctober 6, 2026 | globenewswire.comSee More Headlines SION Stock Analysis - Frequently Asked Questions How have SION shares performed this year? Sionna Therapeutics' stock was trading at $41.14 on January 1st, 2026. Since then, SION stock has decreased by 92.5% and is now trading at $3.07. How were Sionna Therapeutics' earnings last quarter? Sionna Therapeutics, Inc. (NASDAQ:SION) posted its earnings results on Tuesday, November, 10th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.10. When did Sionna Therapeutics IPO? Sionna Therapeutics (SION) raised $180 million in an initial public offering (IPO) on Friday, February 7th 2025. The company issued 10,588,233 shares at a price of $16.00-$18.00 per share. Who are Sionna Therapeutics' major shareholders? Sionna Therapeutics' top institutional shareholders include RA Capital Management L.P. (14.27%), Goldman Sachs Group Inc. (6.01%), Marshall Wace LLP (0.98%) and State Street Corp (0.83%). Insiders that own company stock include Tpg Gp A, Llc, Ra Capital Management, LP, Peter A Thompson, Orbimed Advisors Llc, Bruce Booth, Michael Cloonan and Elena Ridloff. View institutional ownership trends. How do I buy shares of Sionna Therapeutics? Shares of SION stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/10/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SION's financial health is in the Yellow zone, according to TradeSmith. SION has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SION Previous SymbolNASDAQ:SION CIK2036042 Webwww.sionnatx.com Phone(617) 819-2020FaxN/AEmployees59Year FoundedN/APrice Target and Rating Average Price Target for Sionna Therapeutics$42.33 High Price Target$63.00 Low Price Target$5.00 Potential Upside/Downside+1,278.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-39.78% Return on Assets-37.21% Debt Debt-to-Equity RatioN/A Current Ratio13.92 Quick Ratio13.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.32 per share Price / Book0.58Miscellaneous Outstanding Shares45,240,000Free Float42,929,000Market Cap$138.89 million OptionableOptionable Beta1.23 Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:SION) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sionna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sionna Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.